Results 221 to 230 of about 74,181 (306)

Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3180-3190, September 2026.
Aims Vincristine‐induced peripheral neuropathy (VIPN) is a common side effect in children and adolescents treated with vincristine. Assessing VIPN, especially in young children, is challenging due to a lack of sensitive tools. This limits our understanding of the nature and risk factors of VIPN. This study aimed to investigate neurofilament light chain
Peter Erik Lotko Pontoppidan   +8 more
wiley   +1 more source

A TRIP‐nano killer silencing the pain pacemakers

open access: yes
The Journal of Physiology, EarlyView.
Elisabetta Cerbai
wiley   +1 more source

MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 3002-3011, September 2026.
Aminoglycosides are broad‐spectrum antibiotics used in the management of severe infections. Aminoglycosides are associated with nephrotoxicity and ototoxicity. Although dosing strategies such as once‐daily administration and therapeutic drug monitoring have reduced the incidence of nephrotoxicity, ototoxicity remains unpredictable and may occur at ...
John H. McDermott   +16 more
wiley   +1 more source

A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors

open access: yesCancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Atypical teratoid/rhabdoid tumors (ATRTs) are aggressive pediatric brain tumors that are sensitive to proteasome inhibitors in preclinical models. We evaluated the feasibility of combining the proteasome inhibitor, bortezomib, with chemotherapy.
Wan‐Ling Ho   +38 more
wiley   +1 more source

Efficacy and Safety of CAR‐T Cell Therapy in Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia With Central Nervous System Involvement

open access: yesCancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Central nervous system (CNS) involvement in B‐cell acute lymphoblastic leukemia (B‐ALL) is associated with relapse, treatment refractoriness, and poor prognosis. Although chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (R/R) B‐ALL, its efficacy and safety in CNS leukemia (CNSL) remain ...
Yanghong Yu   +3 more
wiley   +1 more source

Intrathecal Ziconotide Long-Term Management in Chronic Postamputation Pain. [PDF]

open access: yesCase Rep Anesthesiol
Mateos RG   +4 more
europepmc   +1 more source

Prolonged Headache in a 13‐Year‐Old Girl With Acute Lymphoblastic Leukemia: A Case of Possible Neuroinflammatory Complication Responsive to Intravenous Immunoglobulin

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Neurological complications in pediatric acute lymphoblastic leukemia (ALL) may result from disease, CNS involvement, or treatment. We report a 13‐year‐old girl with persistent headache and blurred vision suggestive of raised intracranial pressure.
Amereh Hadizadeh   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy